Cambrex (CBM) and Its Peers Head to Head Analysis

Cambrex (NYSE: CBM) is one of 102 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Cambrex to related businesses based on the strength of its analyst recommendations, institutional ownership, earnings, risk, profitability, dividends and valuation.

Profitability

This table compares Cambrex and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cambrex 18.79% 23.42% 16.19%
Cambrex Competitors -2,466.86% -68.47% -7.90%

Earnings and Valuation

This table compares Cambrex and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cambrex $490.64 million $81.67 million 17.67
Cambrex Competitors $8.31 billion $1.11 billion 177.24

Cambrex’s rivals have higher revenue and earnings than Cambrex. Cambrex is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 2.5% of Cambrex shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Cambrex has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Cambrex’s rivals have a beta of 0.94, suggesting that their average share price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cambrex and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambrex 0 0 4 0 3.00
Cambrex Competitors 966 3915 6899 184 2.53

Cambrex currently has a consensus target price of $62.33, suggesting a potential upside of 17.61%. As a group, “Pharmaceuticals” companies have a potential upside of 20.63%. Given Cambrex’s rivals higher probable upside, analysts clearly believe Cambrex has less favorable growth aspects than its rivals.

Summary

Cambrex rivals beat Cambrex on 7 of the 13 factors compared.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply